Table 1.

Incidence of CTC, CTC apoptosis, and CTC clusters

A. Incidence of CTC
CTC/7.5 mL WB ≥ 5 CTC /7.5 mL WB by randomized arm
≥ 1 ≥ 3 ≥ 5 Nab-paclitaxel Nab-paclitaxel + tigatuzumab P
Baseline61.5% (32/52)50.0% (26/52)36.5% (19/52)31.6% (6/19)39.4% (13/33)0.57
Day 1542.3% (22/52)32.7% (17/52)26.9%(14/52)15.8% (3/19)33.3% (11/33)0.17
Day 2938.8% (19/49)28.6 (14/49)26.5%(13/49)22.2% (4/18)29.0% (9/31)0.74
B. Incidence of CTC apoptosis and CTC clusters
CTC apoptosis a CTC clusters b
Baseline Day 15 Day 29 Baseline Day 15 Day 29
5/19 (26.3%)7/14 (50.0%)8/13 (61.5%)8/32 (25.0%)4/22 (18.2%)7/19 (36.8%)
C. Apoptosis according to single versus clustered CTC at any time during the trial
Single CTC CTC cluster
# of single CTC cells % single cell positive for apoptosis # of CTC in the cluster % CTC cluster with 1 cell positive for apoptosis
8,39320%9430.4 %
D. Apoptosis according to single versus clustered CTC at baseline, day 15, and day 29
Baseline Day 15 Day 29
Single cell516/2,678 (19%)363/1,505 (24%)795/4,210 (19%)
Cluster1/161 (0.6%)0/283 (0%)3/499 (0.6%)
  • aOf those ≥5 CTC/7.5 mL WB.

  • bOf those with ≥1 CTC/7.5 mL WB.